Study of LAIR-1(CD305) Expression in Patients with B-Chronic Lymphocytic Leukemia
Ebtsam Salim El-Saeid Salim;
Abstract
B-cell chronic lymphocytic leukemia (B-CLL) results from accumulation of small mature B lymphocytes which have undergone monoclonal expansion in blood, bone marrow and lymphoid organs which is mainly due to inhibition of apoptosis rather than enhanced cell proliferation.
CLL has a typical clinical presentation with highly heterogenous clinical course. Some patients never require a therapeutic intervention while the survival of other patients is short despite early initiation of therapy.
LAIR-1 (also known as CD305) belongs to the family of immune inhibitory receptors, which are involved in controlling the balance of the immune system to prevent improper activation or over activation, which may result in tissue damage or autoimmune diseases.
CLL has a typical clinical presentation with highly heterogenous clinical course. Some patients never require a therapeutic intervention while the survival of other patients is short despite early initiation of therapy.
LAIR-1 (also known as CD305) belongs to the family of immune inhibitory receptors, which are involved in controlling the balance of the immune system to prevent improper activation or over activation, which may result in tissue damage or autoimmune diseases.
Other data
| Title | Study of LAIR-1(CD305) Expression in Patients with B-Chronic Lymphocytic Leukemia | Other Titles | دراسة لير-1 (سى دى 305) فى المرضى المصابين بسرطان الدم الليمفاوى المزمن (بي) | Authors | Ebtsam Salim El-Saeid Salim | Issue Date | 2017 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.